Archives of Cancer Biology and Therapy

The nature of gene mutations induced by ionizing radiation in germ cells and transmitted to offspring remains one of the most important problems in radiation genetics of higher eukaryotes. The data accumulated in this field were obtained by different authors under different experimental conditions which does not give a complete insight about the nature of radiation-induced inherited mutations at different genome levels (chromosome, gene, DNA). 

It is now well accepted that the ionizing radiation-generated reactive oxygen species (ROS), that constitute ~2/3 of the effects of external beam radiation, do not only produce direct tumor cell death, but also affect the surrounding microenvironment. Moreover, this indirect effect of radiation may result in systemic effects, specifically the initiation of an inflammatory response.

Considering their outstanding mechanical character, it is inevitable to utilize titanium and titanium composite for biomedical engineering application [1-6]. However, the particles releasing from these bulks or composites of biomaterials after long term implanting in human body will cause cell apoptosis or cell death, inflammation, bone

Delivery of high-quality cancer care improves oncologic outcomes, including survival and quality of life. The VA National Radiation Oncology (NROP) established the VA Radiation Oncology Quality Surveillance Program (VAROQS) which has developed clinical quality measures (QM) as a measure of quality indices in radiation oncology. We sought to measure quality in community care, assess barriers to data capture, and develop solutions to ensure long term sustainability of continuous quality improvement for veterans that receive dual care, both within the VA and in non-VA community care (NVCC).

In the manuscript entitled “The ion channels and transporters gene expression profile indicates a shift in excitability and metabolisms during malignant progression of Follicular Lymphoma”, we reported recent advances in our understanding of how the gene expression profile of ion channels and transporters (ICT-GEP) contributes to identify specific signatures associated with Follicular Lymphoma (FL), with those FL that acquire chemoresistance after a relapsing-remitting course, and with the more aggressive Diffuse Large Cell Lymphoma (DLBCL), which in some cases represent the evolution of FLs. 

The use of molecular and genomic analysis of a cancer as a means to define a patient-specific treatment is interchangeably referred to as Precision Medicine, Personalized Medicine, or Genomically-directed medicine (herein, collectively PMED). In the foregoing commentary we have focused on PMED approaches related to treatment selection and do not prioritize the development of novel molecular assays used to guide patient diagnostics or prognostication. 

Background: We have recently published SL-BioDP, a web resource for querying, exploration and visualization of potential synthetic lethal targets and possible synergistic drug combinations for 18 cancer types. Methods: From our predictive synthetic lethality model used in SL-BioDP, we inferred TP53 mutation lead to potential synergistic drug combination of Bortezomib and Vorinostat. Here we show, how to extrapolate the drug combination results by combining drug screening data from cancer cell lines and showed the potential synergy of the drug targets, proteasome, and histone deacetylase (HDAC) pathways respectively, for patient survival advantage.

Medullary breast carcinoma (MBC) is a rare tumor, representing 3% to 5% of invasive breast carcinomas. The World Health Organization defines it as a well-circumscribed invasive tumor, composed of poorly differentiated cells, arranged in sheets, without gland formation and a scarce collagen stroma with the presence of a very prominent lymphoplasmacytic infiltrate.

Ricin toxin (RT) is classified as a potential bio-threat agent in assassinations and terrorism due to its extreme toxicity. Due to aerosol RT exposure is the most lethal route, it is urgent to study its injury mechanism. 

Lung cancer remains the leading cause of cancer related death in the United States with mortality rates surpassing breast, prostate, brain, and colorectal cancers combined. Recent data shows that susceptibility for both men and women for developing invasive lung and bronchogenic carcinoma peak after the age of 70 years.

Hypothesis-driven research has dominated biomedical science for at least the past century. There are many papers and grant applications that will have been rejected because they are not hypothesis-driven. For example, Haufe reports that the NIH guidelines for RO1 grants states that “A strong grant application is driven by a strong, solid hypothesis with clear research objectives”.

MicroRNAs (miRNAs) are small non-coding RNAs that modulate protein-coding mRNAs. Numerous miRNAs are expressed in human and 50% of human miRNAs are associated with carcinogenesis. Specific miRNAs are expressed in different cancer tissues and modulation of their expression is associated to different tumor stages and clinical outcomes.

Cardiac Complications are the leading cause of mortality after orthotopic liver transplantation. Advanced liver disease patients with positive DSE are at increased risk. CAD, beta blocker use and NASH are independently associated with cardiac events.

The role for postoperative radiation therapy (PORT) for patients with non–small-cell lung cancer (NSCLC) with mediastinal lymph node (LN) involvement (pN2 disease) is controversial. We performed a SEER analysis comparing surgery alone with PORT among patients with pN2 NSCLC. As we await the final results of the LUNG ART trial, a subset of patients with a high LN positive to sampled (LPR) ratio may benefit from PORT.

Background & Aim: Patients presenting with an array of benign oral mucosal diseases to oral & maxillofacial (OMF) units practicing risk habits such as betel chewing could be at high risk of poor oral health and progressing into Oral Potentially Malignant Disorders (OPMD) or oral cancer. Against this backdrop, we investigated the possible role of selected habits, periodontal disease an oral hygiene in occurrence and prognosis of oral mucosal lesions, among a cohort of patients in Sri Lanka.

Multiple Myeloma (MM) is a malignancy of the antibodyproducing plasma cells found in the bone marrow. In recent years, we have witnessed significant improvements made in both the diagnostic criteria and novel therapies for MM, resulting in the prolonged survival of MM patients. Approved novel therapies include proteasome inhibitors (bortezomib and carfilzomib), immunomodulatory drugs (thalidomide, lenalidomide & pomalidomide), monoclonal antibodies (daratumumab, elotuzumab & isatuximab) and B-cell maturation antigens (Belantamab). Recently, CAR T cell therapy has been FDA approved for MM treatment. Despite these advancements, MM remains an incurable cancer with suboptimal overall survival, with many patients developing relapsed/refractory MM. Plasma cell leukemia (PCL) is a rare and aggressive variant of MM. PCL is classified as either primary PCL, which develops de novo, or secondary PCL, that can arise in the late and advanced stages of MM. 

The cortex, hippocampus, and amygdala are among the brain regions where estrogens may act to improve cognition, memory and mood. In these regions, estrogens have many beneficial effects, including neuroprotection, neurogenesis, as well as neurotrophic, antioxidant, and anti-inflammatory effects [1-2].

The positive prognostic role of the immune environment in colorectal cancer is widely accepted. However, there are few data about the prognostic significance of interleukin-22 in human colorectal cancer which is still debated.

TME contains various cell types (malignant cells, immune cells, fibroblasts, endothelial cells, etc.) and extracellular components (cytokines, growth factors, hormones, extracellular matrix, etc.). Tumor heterogeneity, characterized by each tumor’s distinct TME cellular composition and states and the interplay between these components, may play a critical role in tumor initiation, progression, therapeutic efficacy, and patient survival.

Leveraging the immunomodulatory effects of radiation therapy (RT) for synergy with immunotherapeutic agents for the treatment of cancer is an area of immense interest. A pressing deficiency in the translation of this strategy into the clinic is the lack of clarity on the impact of radiation dose-fractionation on host anti-cancer immune defences.